Metavant and Poxel Announce Positive Topline Safety and PK/PD Results of Imeglimin in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3b/4

21

NEW YORK & BASEL, Switzerland & LYON, France–(BUSINESS WIRE)–Metavant Sciences, a clinical-stage biopharmaceutical company committed to developing innovative therapies for metabolic disorders, and POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced positive topline results from a PK/PD clinical trial for imeglimin…

 

 

 

http://www.businesswire.com/news/home/20190708005685/en/Metavant-Poxel-Announce-Positive-Topline-Safety-PKPD

- Advertisement -